Results 11 to 20 of about 589 (105)

Efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia: stage 2 results from a multicenter phase III study

Platelets, 2022
This phase III, randomized, placebo-controlled study conducted in three stages (6-week, randomized, placebo-controlled stage 1; 24-week, open-label stage 2; and continuous extension stage 3) assessed the long-term efficacy and safety of eltrombopag use ...
Xiaofan Liu, Ming Hou, Junmin Li, Jie Jin, Meijuan Huang, Ziqiang Yu, Xiaojun Xu, Xiaohui Zhang, Renchi Yang   +8 more
doaj   +1 more source

EVALUATION OF THE FREQUENCY OF ARTERIAL AND VENOUS THROMBOSIS AND PREDISPOSING FACTORS IN PATIENTS USING ELTROMBOPAG

Hematology, Transfusion and Cell Therapy, 2021
Objective: Eltrombopag is a small molecule thrombopoietin-receptor agonist used orally for the treatment.There is a high risk of thrombosis associated with the use of Eltrombopag.
Derya Deniz Kurekci, Melda Isevi, Engin Kelkitli, Mehmet Turgut   +3 more
doaj   +1 more source

Use of Eltrombopag in Children With Chronic Immune Thrombocytopenia (ITP): A Real Life Retrospective Multicenter Experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP)

Frontiers in Medicine, 2020
Background: The thrombopoietin receptor agonist eltrombopag has been shown to be safe and effective for children with chronic immune thrombocytopenia (ITP).
Paola Giordano, Giuseppe Lassandro, Angelica Barone, Simone Cesaro, Ilaria Fotzi, Fiorina Giona, Saverio Ladogana, Maurizio Miano, Antonio Marzollo, Margherita Nardi, Lucia Dora Notarangelo, Andrea Pession, Antonio Ruggiero, Giovanna Russo, Paola Saracco, Marco Spinelli, Alessandra Tolva, Assunta Tornesello, Valentina Palladino, Giovanni Carlo Del Vecchio   +19 more
doaj   +1 more source

Evaluation of Eltrombopag in Thrombocytopenia Post Hematopoietic Cell Transplantation: Rertrospective Observational Trial

Hematology/Oncology and Stem Cell Therapy, 2022
Background: Thrombocytopenia remains a life-threatening late complication of HCT with an incidence of 5—20%. Currently, there is no approved drug for the treatment of persistent thrombocytopenia post HCT and platelet transfusion is the maintain stay of ...
H. Samarkandi, M. Al Nahedh, A. Alfattani, F. Alsharif, N. Bakshi, W. Rasheed, F. Alfraih, M. Alhumaid, Nora Alkhudair, S. Alhayli, H. Alsaedi, M. Shaheen, A. Hanbali, S.K. Hashmi, E. Devol, A. Alseraihy, H. Alzahrani, M. Aljurf   +17 more
doaj   +1 more source

Prediction of Clinical Transporter‐Mediated Drug–Drug Interactions via Comeasurement of Pitavastatin and Eltrombopag in Human Hepatocyte Models

CPT: Pharmacometrics & Systems Pharmacology, 2020
A structurally identifiable micro‐rate constant mechanistic model was used to describe the interaction between pitavastatin and eltrombopag, with improved goodness‐of‐fit values through comeasurement of pitavastatin and eltrombopag.
Simon J. Carter, Bhavik Chouhan, Pradeep Sharma, Michael J. Chappell   +3 more
doaj   +1 more source

Eltrombopag improves refractory thrombocytopenia in patients with Sjögren's syndrome

Science Progress, 2022
Introduction: Eltrombopag, a kind of thrombopoietin (TPO) receptor agonist, plays the role on the megakaryocyte to activate the platelet production and rapidly increase the number of circulating platelets in patients with primary immune thrombocytopenia (
Liping Xu, Yan Zhang, Na Lin, Xinwei Song, Qiaoding Dai   +4 more
doaj   +1 more source

Eltrombopag Effectiveness and Tolerability in Chronic Immune Thrombocytopenia: A Meta-Analysis

Clinical and Applied Thrombosis/Hemostasis, 2021
Eltrombopag is an orally administered, non-peptide, thrombopoietin receptor agonist which initiates thrombopoietin signaling and stimulates the production of normally functioning platelet. We aimed to do a systematic review and meta-analysis of currently
Hafiz Abdul Waqas Ahmed MD, Ahmed Taher Masoud MD, Jia Han MD, PhD, Ahmed Adel Sofy MD, Ahmed Saeed Ahmed MD, Ahmed Taha Abdesattart MD, Emmanuel Kwateng Drokow MD, PhD, Kai Sun MD, PhD   +7 more
doaj   +1 more source

A Real-World Observation of Eltrombopag and Recombinant Human Thrombopoietin (rhTPO) in Lymphoma Patients With Chemotherapy Induced Thrombocytopenia

Frontiers in Oncology, 2021
This real-world, observational study aimed to assess and compare the clinical efficacy and safety of eltrombopag with recombinant human thrombopoietin (rhTPO) in the treatment of chemotherapy induced thrombocytopenia (CIT) in patients with lymphoma.
Qiuhua Zhu, Shimei Yang, Wenbin Zeng, Mingjie Li, Zebing Guan, Lanlan Zhou, Hong Wang, Yanan Liu, Yanmin Gao, Shiqiu Qiu, Chaolun Chen, Huan Li, Shanshan Zheng, Yuemei Yuan, Hanling Zhang, Xueyi Pan   +15 more
doaj   +1 more source

Eltrombopag in treatment of refractory primary immune thrombocytopenia: case report

Клиническая онкогематология, 2013
We present clinical case that demonstrates high efficiency of eltrombopag for the treatment of immune thrombocytopenia. It is shown that stable effect may persist after a course of eltrombopag therapy during 2 months. Eltrombopag is highly effective with
G. A. Dudina, I. N. Kontievskiy, V. N. Perova   +2 more
doaj   +1 more source

Switching between eltrombopag and recombinant human thrombopoietin in patients with immune thrombocytopenia: an observational study

Chinese Medical Journal, 2022
Background:. Recombinant human thrombopoietin (rh-TPO) and eltrombopag are two distinct TPO receptor agonists (TPO-RAs) with different mechanisms. During the pandemic, when immunosuppressive medications are controversial, switching to another TPO-RA may ...
Xuan Cai, Haixia Fu, Xiangyu Zhao, Jin Lu, Qian Jiang, Yingjun Chang, Xiaojun Huang, Xiaohui Zhang, Yuanyuan Ji   +8 more
doaj   +1 more source